Gavin Ovsak

Dr. Gavin Ovsak

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
GOGavin Ovsak
Gavin Ovsak
TGTong J. Gan
Tong J. Gan

4 September 2026 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Closed access
PDF file
ENEric Hoang Nguyen
Eric Hoang Nguyen
KHKevin Hoffman
Kevin Hoffman
SGSunny Gotewal
Sunny Gotewal
AWAshley Wetzig
Ashley Wetzig
AWAlexander Wetzig
Alexander Wetzig
ETEdward H Tsai
Edward H Tsai
Background: Phantom limb syndrome (PLS) is a common complication following below-knee amputations (BKA) causing painful and/or nonpainful sensations in the absent limb. Peripheral nerve blocks (PNBs) are used for perioperative analgesia, but their association with PLS risk remains unclear. This study sought to evaluate potential associations regarding PLS incidence after BKA with and without PNBs. Methods: This retrospective cohort study was conducted using Epic Cosmos data from 2016 to 2025. Adults undergoing elective BKA were identified using Current Procedural Terminology codes 27880-27889 and categorized by PNBs versus none. The primary outcome was PLS diagnosis within 12 months of surgery using International Classification of Diseases, 10th Revision, Clinical Modification codes (G54.6, G54.7). Relative risks (RRs) were estimated using Mantel-Haenszel stratification adjusted for age, sex, and race only, with subgroup analysis by comorbidity burden. Secondary outcomes included length of stay (LOS). Results: Among 38 433 patients, 7430 (19.3%) received perioperative PNBs and 31 003 (80.7%) did not. PLS diagnosis coding occurred in 18.8% of the PNB group versus 15.1% of the non-block group (absolute difference 3.7%). Analysis adjusted for age, sex, and race only did not change the association (Mantel-Haenszel RR 1.24, 95% CI 1.20 to 1.28). PNBs were associated with a shorter LOS. All estimates should be considered exploratory associations. Conclusions: In this multicenter electronic health record-based cohort, exploratory analysis showed that perioperative PNB use was associated with increased rates of documented PLS coding across subgroups. However, the overall RR increase is modest. The observed association may reflect residual confounding by indication and differential surveillance rather than a causal effect. PNBs still remain appropriate for improving acute pain and reducing LOS. Prospective studies are needed to clarify causality and inform prevention strategies.

18 August 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
MZMorgan Bou Zerdan
Morgan Bou Zerdan
MMMark F. Munsell
Mark F. Munsell
GOGavin Ovsak
Gavin Ovsak
JHJeffrey How
Jeffrey How
RWRoni Nitecki Wilke
Roni Nitecki Wilke
MIMaria D. Iniesta
Maria D. Iniesta

2 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NCNicolas Andres Cortes-Meja
Nicolas Andres Cortes-Meja
JLJuan Jose Guerra Londono
Juan Jose Guerra Londono
TITarikul Islam
Tarikul Islam
HLHeather A. Lillemoe
Heather A. Lillemoe
GOGavin Ovsak
Gavin Ovsak
JCJuan Cata
Juan Cata
Background: Adjuvant therapies improve disease-free and cancer-specific survival in digestive tract malignancies. Return to intended oncological therapy (RIOT) measures how promptly patients resume these treatments after cancer resection. Because sugammadex has demonstrated superior postoperative outcomes compared to neostigmine, we hypothesize that its use may increase the likelihood and timeliness of RIOT in patients undergoing digestive tract cancer surgery. Methods: Adults (≥18 years) undergoing gastrointestinal, hepatobiliary cancer resection, or liver resection for limited metastases between January 2016 and December 2017 were retrospectively analyzed. Patients were grouped by neuromuscular blockade reversal agent (neostigmine vs. sugammadex). The primary outcome was RIOT within 90 days; secondary outcomes included RIOT within 180 days, time-to-RIOT, hospital length of stay, ICU admission, and readmissions. Results: Of 4358 records screened, 1081 met the inclusion criteria: 273 (25.2%) patients with neostigmine and 808 (74.8%) with sugammadex. Patients in the neostigmine group were slightly younger, and racial distribution differed modestly, but sex, BMI, ASA class, comorbidity, cancer type, and stage were comparable. Median reversal doses were 5 mg and 200 mg, respectively. Anesthesia duration, hospital and ICU length of stay, readmissions, and ICU use showed no significant differences. RIOT frequency was also similar across groups, except for modestly higher radiotherapy resumption with neostigmine at 90 and 180 days. Overall, perioperative and oncological outcomes were largely comparable between groups. Conclusions: Sugammadex and neostigmine showed similar RIOT rates, with only a modest difference in radiotherapy resumption. Larger studies are needed to elucidate the potential benefits of sugammadex, particularly regarding long-term oncological outcomes and treatment continuity.

31 July 2026 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
ENEduardo Nunez-Rodriguez
Eduardo Nunez-Rodriguez
GCGuanqing Chen
Guanqing Chen
GOGavin Ovsak
Gavin Ovsak
JSJose Miguel Soliz
Jose Miguel Soliz
EKEvan D. Kharasch
Evan D. Kharasch
JCJuan Cata
Juan Cata